Evidence map›Paper›PMID 39497815›Full record

ArticleFrontiers in immunology2024

Clones reactive to apoptotic cells and specific chemical adducts are prevalent among human thymic B cells.

Andrea Hertel, Talita Aguiar, Shunya Mashiko, Sarah Núñez, Carolina Moore, Baoshan Gao, Mattea Ausmeier, Poloumi Roy, Emmanuel Zorn

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrea HertelColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, United States.
Talita AguiarColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, United States.
Shunya MashikoColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, United States.
Sarah NúñezColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, United States.
Carolina MooreTransplant Center, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Baoshan GaoTransplant Center, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Mattea AusmeierColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, United States.
Poloumi RoyColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, United States.
Emmanuel ZornColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, United States.

Funding

Thymic plasma cells as a source of protective natural antibodies in human neonatesR21AI174414 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ZORN, EMMANUEL · 2023 to 2024
$452k
Source and homeostatic functions of anti-adduct IgM in humansR21AI176641 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ZORN, EMMANUEL · 2023 to 2024
$452k
NIAID NIH HHS R21 AI174414NIAID NIH HHS R21 AI176641
6 · The paper itself

Abstract

Introduction: Thymus resident B cells were described more than 40 years ago. In early human life, these cells are found predominantly in the medulla and overwhelmingly display an unswitched IgM+ phenotype. The reactivity of thymic IgM B cells, however, is still unclear. Methods: Here, we generated 120 IgM-producing B cell clones from 3 separate thymus specimens obtained from infant, adolescent, and adult donors. Using flow cytometry and a unique high-dimensional ELISA platform, we investigated the clones' reactivity to apoptotic cells as well as to common chemical adducts exposed on modified amino acids and other macromolecules. Results: Regardless of the age, approximately 30-40% of thymic IgM B cells reacted to apoptotic cells. Further, 30-40% displayed reactivity to at least one adduct, including malondialdehyde, Homocysteine, and NEDD 8. Four distinct reactivity patterns were identified through this profiling. Notably, a significant association was observed between reactivity to apoptotic cells, and to one or more adducts, suggesting that the same determinants were recognized in both assays. Additionally, thymic IgM B cells reactive to adducts were more likely to recognize intra-nuclear or intra-cytoplasmic structures in Hep-2 cells as revealed by immunofluorescence staining. Conclusion/Discussion: Collectively, our findings suggest that thymic IgM B cells actively uptake apoptotic bodies and cellular debris in the medulla by binding specific chemical adducts. This mechanism could underpin their antigen-presenting function and further support their role in T-cell negative selection.

Indexed as

ApoptosisB-LymphocytesImmunoglobulin MThymus GlandAdolescentAdultClone CellsFemaleHomocysteineHumansInfantMaleMalondialdehydeYoung AdultHomocysteineImmunoglobulin MMalondialdehydeapoptotic cellschemical adductsnatural antibodiespolyreactivitythymic B cells

Identifiers

PMID39497815
PMCPMC11532181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.